fbpx Skip to main content


Commercialization of Our Medicines

Commercialization: Ensuring the Reach of Our Medicines to Patient Populations on a Global Scale

“I’m deeply inspired by the legacy of this team, which for more than two decades has been a world leader in the development of transformational medicines, establishing one of the strongest, first-in-class portfolios and pipelines in the industry.”

Candice Long

Worldwide VP, Immunology Global Commercial Strategy Organization

We have redefined the standard of care in immunology over the past two decades. The work of our dedicated team has propelled Janssen to a leadership position with cutting-edge treatments that address the needs of patients living with autoimmune and inflammatory diseases. For more than 20 years, we have led the discovery, development and commercialization of monoclonal antibodies.

We introduced the first anti-tumor necrosis factor (TNF) monoclonal antibody to the market, leading a category of new medicines that have changed the way chronic conditions in gastroenterology, rheumatology and dermatology are treated. We went on to establish the essential roles for inhibiting interleukin (IL)-12 and IL-23 in immune-mediated inflammatory diseases. Today, biologic medicines have been used to treat millions of patients across a broad spectrum of conditions, targeting the underlying drivers of disease—not just the symptoms.

Together with medical affairs and commercial partners, our best-in-class commercial capabilities and global infrastructure make us a frontrunner in bringing innovative treatments for devastating diseases to diverse patient populations around the world.



Air-liquid interface culture of colonic epithelial cells; Clara Moon, Janssen R&D